

Sélection des publications 2014 de l'équipe 2

Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras Z, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V.
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.
Leukemia. 2014, 28 : 629-641

Cornet E, Tomowiak C, Tanguy-Schmidt A, Lepretre S, Dupuis J, Feugier P, Devidas A, Mariette C, Leblond V, Thiéblemont C, Validire-Charpy P, Sutton L, Gyan E, Eisenmann JC, Cony-Makhoul P, Ysebaert L, Troussard X;
on the behalf of the Société Française d'Hématologie.
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.
Br J Haematol. 2014, 166 : 390-400

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O.
ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases.
PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.

Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P.
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.
Leuk Res Rep. 2014, 3 : 58-61

Herr F, Lemoine R, Gouilleux F, Meley D, Kazma I, Heraud A, Velge-Roussel F, Baron C, Lebranchu Y.
IL-2 Phosphorylates STAT5 To Drive IFN- γ Production and Activation of Human Dendritic Cells.
J Immunol. 2014, 192 : 5660-5670